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Smoke constituents can induce DNA adducts that cause mutations and lead to lung cancer. We have analyzed DNA adducts and
polymorphisms in two DNA repair genes, for example, XRCC1 Arg194Trp and Arg399Gln genes and XRCC3 Thr241Met gene, in
34 lung cancer cases in respect to 30 subjects with benign lung cancer disease and 40 healthy controls. When the study population
was categorized in base to the number of risk alleles, adducts were signiﬁcantly increased in individuals bearing 3-4 risk alleles
(OR = 4.1 95% C.I. 1.28–13.09, P = .009). A signiﬁcant association with smoking was noticed in smokers for more than 40 years
carrying 3-4riskalleles (OR = 36.38, 95% C.I.1.17–1132.84, P = .040). A not statistically signiﬁcant increment of lung cancer risk
was observed in the same group (OR = 4.54, 95% C.I. 0.33–62.93, P = .259). Our results suggest that the analysis of the number
of risk alleles predicts the interindividual variation in DNA adducts of smokers and lung cancer cases.
1.Introduction
Lung cancer is a leading cause of cancer death in the world
[1]. Advances in the treatment of locally advanced lung
c a n c e rh a dn oi m p a c to no v e r a l l5 - y e a rs u r v i v a lr a t e sf r o m
this disease that remains only of 15%. Although the rates of
lung cancer mortality have started to decrease in countries
where smoking habits have been modiﬁed, the projections
a r en o to p t i m i s t i cb e c a u s eo ft h er e c e n ts u r g ei nt o b a c c o
consumption among young people. In addition, even if
smoking habits could be modiﬁed signiﬁcantly, the long
lag time between peak of tobacco consumption and the
development of lung cancer will assure a long life for this
epidemic.
The role of tobacco smoking in the aetiology of lung
cancer has been widely evaluated [2]. Many compounds
present in the smoke of cigarettes, such as the polycyclic
aromatic hydrocarbons (PAH), induce DNA adducts after
metabolic activation [3]. Unrepaired DNA adducts can
cause mutations, including mutational hot spots in p53
tumour suppressor gene [4] ,a n dl e a dt ou n r e g u l a t e dc e l l
growth and cancer. Increased DNA adduct levels have been
suggested to be predictive of lung cancer risk, reﬂecting both
the environmental exposure to carcinogens than individual
susceptibility [5–8].
It has been hypothesized that interindividual diﬀerence
in lung cancer risk may be due to diﬀerences in DNA repair.
In support of this hypothesis, diﬀerent studies have indicated
that DNA variation in DNA repair genes may inﬂuence
cancersusceptibility [9].Ourgrouphasconductedanumber
of studies that have shown associations between DNA
polymorphisms in DNA repair genes, mainly in XRCC1 (X-
ray repair cross complementing) and XRCC3 genes, cancer,
and/or DNA adducts [10–14] and unpublished results.2 Journal of Nucleic Acids
Thus, we have decided to extend our analysis to the
individuals included in a lung cancer case-control study.
In this study, we have analyzed the levels of DNA adducts
and DNA polymorphisms in two DNA repair genes, for
example, XRCC1 Arg194Trp and XRCC1 Arg399Gln, and
XRCC3 Thr241Met polymorphisms, representing the base
excision repair (BER) and the double-strand breaks repair
(DSB)pathways,inlungcancercasesinrespecttoindividuals
with benign lung disease and to healthy controls. Then, we
decided to investigate the combination of the variant allele/s
of XRCC1 Arg194Trp and Arg399Gln polymorphisms with
the wild type allele of XRCC3 Thr241Met. The analysis
of the eﬀects of diﬀerent combinations of DNA repair
polymorphisms on DNA adducts has been done under the
assumption that the combination of polymorphisms can
have additive or more than additive eﬀects on DNA adduct
formation.
2.MaterialsandMethods
2.1. Study Population. Peripheral blood samples were col-
lected, after written informed consent to participate in the
present study, from 34 nonsmall cell lung cancer patients
(26 males and 8 females, mean age 63.4 years) and from
30 (22 males and 8 females, mean age 63.5 years) subjects
with benign lung diseases admitted to the National Cancer
Institute and San Martino Hospital, Genoa, Italy. 40 controls
(25 males and 15 females, mean age 63.4 years) were
r e c r u i t e df r o mag r o u po fb l o o dd o n o r s .L u n gc a n c e rc a s e s
were asked to participate in the study after the diagnosis,
but before radio and chemotherapy. The group of benign
lung diseases was formed by subjects aﬀected by Chronic
Obstructive Pulmonary Disease (COPD), asthma, and pneu-
moconiosis. A standard questionnaire was administered to
all volunteers by personal interview at the time of blood
collection. Smoking status was deﬁned as smoker, within the
last year, former smoker, at least one year before diagnosis,
and nonsmoker.
2.2. DNA Adduct and Polymorphism Analyses. Peripheral
blood lymphocytes (PBLs) were separated from 5mL freshly
collected whole blood by centrifugation on a Ficoll gradient.
PBL DNA was extracted and puriﬁed using a method
that requires RNA and protein digestion and extraction
with organic solvents [13]. DNA samples were stored at
−80
◦C until laboratory analysis. PBL DNA adducts were
analysed using the nuclease P1 modiﬁcation of the 32P-
postlabelling technique [13]. DNA samples (1–5μg) were
digested with micrococcal nuclease (32.17mU) and spleen
phosphodiesterase (21.6mU). Hydrolized DNA was treated
with nuclease P1 (110mU) for 30
 . The nuclease P1 resis-
tant DNA samples were then labelled by incubation with
25μCi of carrier-free [γ-32P]ATP (3000Ci/mM) and T4-
polynucleotide kinase (112.5mU). The obtained 32P-labelled
samples were analysed using 1.0M sodium phosphate, pH
6.8.DNAadductresolutionwasachievedusing4.0Mlithium
formate, 7.5M urea, pH 3.5 and 0.65M lithium chloride,
0.45M Tris base, 7.7M urea, pH 8.0. Chromatograms were
ﬁnally developed using 1.7M sodium phosphate pH 5.0.
Detection and quantiﬁcation of PBL DNA adducts and
normal nucleotides (nn) were obtained by storage phosphor
imaging techniques employing intensifying screens [15].
After background subtraction, the levels of DNA adducts
were expressed such as relative adduct labelling (RAL)
= screen pixel in adducted nucleotides/screen pixel in
nn.
Polymerase Chain Reaction followed by enzymatic diges-
tion was used for the genotyping of XRCC1 Arg194Trp and
Arg399Gln, and XRCC3 Thr241Met [12].
2.3. Statistical Analysis. Logistic regression analysis was car-
ried outtocalculateOddsRatios(ORs)adjusted fordiﬀerent
covariates (i.e., age, sex, smoking, and DNA polymorphisms,
as appropriate) categorizing DNA adduct levels by RAL
m e d i a nv a l u e( a b o v e / b e l o w0 . 1D N Aa d d u c t sp e r1 0 8 nn).
A multiple regression analysis has also been performed
grouping individuals according to the number of at risk
alleles. A P-value less than or equal to 5% was considered
signiﬁcant. All the analyses were performed by the statistical
package SPSS.
3. Results and Discussion
Genotype and allele frequencies were calculated by counting,
and genotype distributions were in Hardy-Weinberg equi-
librium. Genotype frequencies were, respectively: XRCC1
Arg194Arg =88.8%,Arg194Trp =11.2%,XRCC1Arg399Arg
= 38.5%, Arg399Gln = 49%, Gln399Gln = 12.5%, XRCC3
Thr241Thr = 40%, Thr241Met = 41%, and Met241Met =
19%, in keeping with those reported previously [9].
Characteristics of the study population are summarized
in Table 1. PBL DNA adducts were increased in former and
current smokers in respect to nonsmokers. The highest levels
ofDNAadductsweredetectedinindividualsthatreportedto
smoke for more than 40 years. A slightly increment of DNA
damage was observed in benign lung disease and lung cancer
patients in respect to controls.
Multiple regression analysis shows an increased fre-
quency of PBL DNA adducts in smokers for more than 40
years (OR=5.28, 95% conﬁdence interval (C.I.) 1.00–27.72,
P = .049). A signiﬁcant trend with increasing number of
smoked cigarettes was found (P for trend <.05). After the
previous cited adjustments, no diﬀerences were observed
comparing controls with benign lung diseases and lung
cancer patients.
When the associations of DNA adducts with DNA
polymorphisms were considered, a null association with
XRCC1 Arg194Trp and Arg388Gln polymorphisms was
found (OR=4.08, 95% C.I. 0.77–21.48, P = .098 and
OR=1.32, 95% C.I. 0.34–5.18; P = .689, resp.). Conversely,
a statistically signiﬁcant inverse eﬀect was observed with
XRCC3 Thr241Met polymorphism (OR=0.17, 95% C.I.
0.05–0.61, P = .006).
Then, we investigated the combination of the variant
allele/s of XRCC1 Arg194Trp and Arg399Gln polymor-
phisms with the wild type allele of XRCC3 Thr241Met.Journal of Nucleic Acids 3
Table 1: Means of DNA adducts ± standard error (SE) for diﬀerent variables considered in the study plus the parameter estimates of the
multivariate regression model.
Na Means
b ± S.E. Odds Ratio C.I. P-value
Gender
Womanc 31 1.2 ± 0.31
Male 73 1.3 ± 0.2 0.65 0.19–2.16 .480
Age (years)
Per unit 104 1.3 ± 0.2 1.02 0.97–1.06 .516
Smoking habit
Nonsmokerc 21 0.8 ± 0.41
Former smoker 44 1.0 ± 0.3 1.60 0.39–6.58 .517
Smoker <40 years 11 1.5 ± 0.7 2.38 0.41–13.90 .336
Smoker ≥40 years 27 2.0 ± 0.5 5.28 1.00–27.72 .049
Status
Controlsc 40 1.0 ± 0.31
Benign lung disease 30 1.3 ± 0.4 0.93 0.28–3.03 .898
Lung cancer 34 1.5 ± 0.4 1.17 0.39–3.47 .783
XRCC1 Arg194Trp
Arg/Argc 87 1.1 ± 0.21
Arg/Trp 11 2.6 ± 1.1 4.08 0.77–21.48 .098
XRCC1 Arg399Gln
Arg/Argc 37 0.9 ± 0.21
Arg/Gln 47 1.4 ± 0.3 0.93 0.36–2.39 .882
Gln/Gln 12 1.8 ± 1.0 1.32 0.34–5.18 .689
XRCC3 Thr241Met
Thr/Thrc 40 1.5 ± 0.41
Thr/Met 41 1.2 ± 0.3 0.38 0.15–0.97 .043
Met/Met 19 0.7 ± 0.4 0.17 0.05–0.61 .006
Number of risk alleles
0-1c 25 0.8 ± 0.41
23 1 1 .0 ± 0.3 0.92 0.31–2.69 .877
3-4 38 2.0 ± 0.5 4.1 1.28–13.09 .009
aSome ﬁgures do not add up to the total because of missing values.
bLevels per 108 normal nucleotides.
cReference level.
The choice was based on the diﬀerent association of XRCC1
and XRCC3 polymorphisms with lung cancer risk, for
example, positive for XRCC1 Arg194Trp and Arg399Gln and
negative for XRCC3 Met241Met [9, 16, 17]. The analysis
of the eﬀect of diﬀerent combinations of DNA repair
single nucleotide polymorphisms on DNA adducts has been
performed under the assumption that the combination of
diﬀerent polymorphisms can have additive or more than
additive eﬀects.
When the study population was categorized in base to
the number of risk alleles, the levels of DNA adducts were
statistically signiﬁcantly increased in individuals bearing
three-four risk alleles (OR=4.1 95% C.I. 1.28–13.09, P =
.009). A signiﬁcant association with smoking was noticed
in smokers for more than 40 years carrying 3-4 risk alleles
(OR=36.38, 95% C.I. 1.17-1132.84, P = .040). A not
statistically signiﬁcant increment of lung cancer risk was
observed inthesamegroup(OR=4.54, 95%C.I. 0.33–62.93,
P = .259). A signiﬁcant trend with increasing the number
of risk alleles was also observed (P for trend <.05). Any
association with benign lung diseases was not found.
Tobacco smoking is recognised as the primary pre-
ventable cause of human cancer. Therefore, many studies
have explored the inﬂuence of smoking on the levels of
DNA adducts in nucleated blood cells in order to identify an
early and sensitive biomarker of eﬀective intake of tobacco
carcinogens [18].
I no u rs t u d y ,w eh a v ea n a l y z e dP B L sa ss u r r o g a t ea n d
more accessible tissues than bronchial biopsies, and we
compared the levels of DNA adducts in patients with lung
cancer in respect to those with benign lung diseases and
controls. Our aim was to evaluate whether the levels of4 Journal of Nucleic Acids
Table 2: Means of DNA adducts ± standard error (SE) case-control status considering the number of DNA repair risk alleles plus the
parameter estimates of the multivariate regression model.
Na Means
b ±S.E. Odds Ratio C.I. P-value
0-1 risk alleles
Smoking habit
Nonsmokerc 61 .7 ±1.51
Former smoker 12 0.4 ±0.1 0.08 0.00–9.76 .302
Smoker <40 years 2 0.3 ±0.2 0.33 0.00–67.26 .686
Smoker ≥40 years 5 1.3 ±1.1 0.16 0.00–27.05 .480
Status
Controlsc 13 1.3 ±0.71
Benign lung disease 4 0.4 ±0.1 1.23 0.08–19.30 .884
Lung cancer 8 0.5 ±0.2 0.43 0.05–4.00 .458
2r i s ka l l e l e s
Smoking habit
Nonsmokerc 70 .4 ±0.11
Former smoker 10 0.7 ±0.4 2.46 0.12–50.98 .560
Smoker <40 years 5 0.8 ±0.6 0.86 0.03–28.37 .933
Smoker ≥40 years 9 1.7 ±0.6 20.91 0.62–709.04 .091
Status
Controlsc 12 0.5 ±0.21
Benign lung disease 7 1.1 ±0.6 1.11 0.12–10.00 .928
Lung cancer 12 1.3 ±0.5 2.39 0.25–22.62 .447
3-4 risk alleles
Smoking habit
Nonsmokerc 50 .4 ±0.21
Former smoker 20 1.7 ±0.7 9.47 0.52–173.16 .130
Smoker ≥40 years 9 2.9 ±1.3 36.38 1.17–1132.84 .040
Status
Controlsc 12 1.5 ±0.61
Benign lung disease 15 2.1 ±0.9 0.45 0.06–3.69 .460
Lung cancer 11 2.3 ±1.1 4.54 0.33–62.93 .259
aSome ﬁgures do not add up to the total because of missing values.
bLevels per 108 normal nucleotides.
cReference level.
DNA adducts were associated with benign or malignant lung
chronic diseases. The question of the utility of PBLs as a
valid surrogate for a speciﬁc organ like lung, representing the
events occurring in the target tissue, is still open [19]. Nev-
ertheless, some studies have indicated that the use of PBLs
such as a biological marker, may help in the identiﬁcation of
subjects at elevated risk [6–8]. PBLs are considered suitable
to monitor environmental and occupational carcinogen
exposure and to estimate the burden of DNA adducts in
respiratory tissue [5, 20–22]. In fact, increased amount of
PBL DNA adducts have been found among subjects heavily
exposed to air pollution [21]. The relationship with target
tissue DNA adducts may vary between type of carcinogen
and target tissue although signiﬁcant correlations have been
seen between the levels of DNA damage in PBLs and
bronchial mucosa [20].
Uppermost, we have considered the eﬀect of smoking
on DNA adduct levels. Our ﬁndings show that the levels
of DNA adducts of smokers were higher than those of
former and nonsmokers. Our ﬁnding shows that PBL
DNA adduct may reﬂect exposures to carcinogens, such
as those contained in tobacco smoke better than other
surrogate tissues, such as leukocyte DNA adducts. However,
discrepant results have been also reported with PBLs [18].
This is probably due to methodical diﬀerences in the 32P-
DNA postlabelling protocol applied from research laborato-
ries.
Next results show that the eﬀect of smoking on DNA
damage was more marked in the subjects that reported to
smoke for more than 40 years. Although detailed infor-
mation on smoking history, for example, number of pack
of cigarettes smoked per years was missing, our ﬁndingsJournal of Nucleic Acids 5
support the hypothesis that the formation of DNA adducts
is signiﬁcantly inﬂuenced by chronic carcinogen exposure.
Furthermore, when study population was subgrouped for
the number of risk alleles, a signiﬁcant association with
smoking was observed in the subjects carrying three or more
risk alleles who reported to smoke for more than 40 years.
Conversely, no eﬀect of smoking was observed in smokers
bearing one or less risk allele.
The contribution of duration of exposure to cigarette
smoke has important implications for both research studies
and prevention strategies. It has been shown that the age
at ﬁrst exposure and duration are associated inﬂuences to
the levels of DNA adducts [23]. Smoking during adolescence
has been shown to produce physiological changes leading to
increased persistence of DNA adducts less, and subjects who
begin smoking very early in life tend to be heavy smokers
[23]. Two large epidemiological studies demonstrated that
duration is more important than intensity of cigarette smok-
ing in predicting lung cancer risk [24, 25]. Herein reported
results support in part this hypothesis, thus shedding light
on the mechanisms involved in the aetiology of smoking
related cancers. It is likely that a plateau of the formation
of DNA adducts is reached at these time points [5]. In
fact, the persistence of DNA adducts in PBLs is less than
one decade, which is the maximum lifespan for long-living
lymphocytes.
Our next results show that DNA adduct levels were com-
parable in individuals with benign lung disease or with lung
cancerandincontrols.However,whenspeciﬁccombinations
ofvariantalleleswereinvestigated,anotsigniﬁcantincreased
lungcancerriskwasobservedinindividualsbearingthesame
number of risk alleles.
In a meta-analysis of cancer and bulky DNA adducts
[26], DNA damage has been reported to be predictive
of lung cancer, particularly in smokers. In Veglia’s meta-
analysis, smokers presented a signiﬁcant diﬀerence between
lung cancer cases and controls, with patients having 83%
higher amount of DNA adducts than controls. We know
that the interpretation of the meta-analysis is limited by
the fact that in case-control studies, the level of biomarker
may reﬂect the presence of cancer disease rather than its
aetiology. However, an exception is represented by three
cohort studies, in which DNA adducts have been found
to be prospectively predictive of lung cancer outcome [6–
8]. The importance of these studies is based on the fact
that biomarker measurement in PBLs collected several years
before cancer onset ruled out the possibility that the higher
levels of DNA damage were reﬂecting metabolic changes
associated with cancer.
NoincrementofDNAadductshasbeenfoundinsubjects
with diﬀerent benign bronchial pathologies, such as COPD,
asthma, and pneumoconiosis, characterized by important
inﬂammatoryprocessesinrespecttocontrols.However,such
inﬂammatory phenomena can inﬂuence DNA adduct levels
in lung target cells by increasing the biologically eﬀective
dose of PAH [27]. This hypothesis is consistent with a
previous case-control study where the levels of DNA adducts
in individuals with inﬂammatory diseases were signiﬁcantly
higher than those of controls [28].
DNA damage primarily reﬂects exposures to carcinogens
but is modulated by inherited and acquired susceptibilities.
Age, gender, and life-style and dietary habits have been
reported to inﬂuence levels of DNA adducts [5, 29, 30]. DNA
adducts may be also inﬂuenced by the individual’s ability
to remove DNA adducts undergoing from interindividual
variability [31]. Although the main pathway for removal
of bulky DNA adducts is nucleotide excision repair, it has
been shown that BER and DSB repair mechanisms may
participate in bulky DNA adduct repair, supporting the
association of XRCC1 and XRCC3 polymorphisms with
such kind of DNA damage [32, 33]. In this study we
observed an eﬀect of XRCC3 Thr241Met polymorphism
on DNA adducts. Positive nonstatistically signiﬁcant asso-
ciations with XRCC1 Arg194Trp and Gln399Gln geno-
types were found whereas an inverse signiﬁcant association
was detected in XRCC3 Met241Met carriers. Our ﬁndings
are in keeping with previous studies showing that the
variant alleles of the XRCC1 Arg399Gln polymorphism
is associated with DNA adducts [10, 12, 13]. A recent
pooled analysis has shown a protective eﬀect conferred
by XRRC3 241Met allele carriers against lung cancer
[16]. However, other studies have reported higher levels
of DNA damage in individuals with XRCC1 Arg194Arg
and XRCC3 Met241Met genotypes [12, 33]. Our results
suggest that case-control studies are more indicative for the
determination of genetic susceptibility than cross-sectional
studies.
To study the eﬀect of diﬀerent combinations of DNA
repair single nucleotide polymorphisms on DNA adducts,
we have investigated the combination of the variant allele/s
of XRCC1 Arg194Trp and Arg399Gln polymorphisms with
the wild type allele of XRCC3 Thr241Met. This was based
on the diﬀerent association of XRCC1 and XRCC3 poly-
morphisms with lung cancer risk, for example, positive
for XRCC1 Arg194Trp and Arg399Gln and negative for
XRCC3 Thr241Met [9, 16, 17, 34]. Our ﬁndings show
that the combination of diﬀerent polymorphisms can have
additive eﬀects on the levels of DNA adducts. In fact,
when the number of risk alleles was analyzed, DNA adducts
were higher in individuals carrying three-four risk alleles.
Furthermore, when our population was categorized in base
to the number of risk alleles, the association between
smoking and lung cancer risk tended to be present in the
same individuals bearing three-four risk alleles. Although
statistical signiﬁcances were seen in our analyses, our study
is underpowered, and larger studies are needed to conﬁrm
the associations between DNA polymorphisms, cancer, and
DNA adducts.
Furthermore, a previous report has shown that smoking
is strong harmful factor that can eliminate the eﬀect of
DNA polymorphisms of DNA repair genes on lung cancer
susceptibility [34]. Smoking could lead to cancer due to its
toxic eﬀect regardless of whether individuals have polymor-
phisms with low repair proﬁciency. Thus, the examination of
the eﬀect of diﬀerent combinations of DNA polymorphisms
for the prediction of lung cancer susceptibility could be
more useful in nonsmokers exposed to relatively minor
environmental factors.6 Journal of Nucleic Acids
4. Conclusions
The results of the present study support the utilisation of
PBLs as surrogate and more accessible tissues than bronchial
biopsies. In fact, we have observed a stronger eﬀect of
smoking on DNA adducts of 40 years smokers. When study
population was subgrouped for number of risk alleles, the
association with smoking was concentrated in carriers of 3-
4 risk alleles that reported to have smoked for more than
40 years. A nonsigniﬁcant increased lung cancer risk was
observed in individuals bearing the same number of risk
alleles. Our results suggest that analysis of risk alleles can
predict the interindividual variation in DNA adduct levels
observed in smokers and lung cancer cases.
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